Author

C. F. Lusi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

G. I. Kane· 2 shared P. U. Atukorale· 2 shared A. Brown· 1 shared A. Monahan· 1 shared A. Nagar· 1 shared A. Nandy· 1 shared C. L. Grimes· 1 shared C. N. Parikh· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. I. Kane

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 18, 2023

Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer

L. Chibaya, C. F. Lusi, K. D. DeMarco…·M. A. Ruscetti

This paper combines nanoparticle-delivered immune agonists with senescence-inducing agents to enhance T cell responses and control pancreatic cancer in preclinical models.

DOI 10.1101/2023.09.18.558307

mousehuman

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 29, 2022

Methotrexate inhibition of muropeptide transporter SLC46A2 controls psoriatic skin inflammation

R. Bharadwaj, C. F. Lusi, S. Mashayekh…·N. Silverman

The paper shows that SLC46A2 transports DAP-muropeptides to activate NOD1 in keratinocytes, and methotrexate inhibits this transport, reducing psoriatic inflammation.

DOI 10.1101/2022.09.29.509906

mouseexperimental assay

𝕏 PostBluesky